rs35687416
Variant summary
Our verdict is Likely benign. The variant received -1 ACMG points: 2P and 3B. PM2BP4_ModerateBP7
The NM_016308.3(CMPK1):c.240G>A(p.Gln80Gln) variant causes a synonymous change involving the alteration of a non-conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a benign outcome for this variant. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar.
Frequency
Consequence
NM_016308.3 synonymous
Scores
Clinical Significance
Conservation
Publications
Genome browser will be placed here
ACMG classification
Our verdict: Likely_benign. The variant received -1 ACMG points.
Variant Effect in Transcripts
ACMG analysis was done for transcript: NM_016308.3. You can select a different transcript below to see updated ACMG assignments.
RefSeq Transcripts
| Sel. | Gene | Transcript | Tags | HGVSc | HGVSp | Effect | Exon Rank | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|---|
| CMPK1 | MANE Select | c.240G>A | p.Gln80Gln | synonymous | Exon 2 of 6 | NP_057392.1 | P30085-3 | ||
| CMPK1 | c.144G>A | p.Gln48Gln | synonymous | Exon 2 of 6 | NP_001353064.1 | P30085-1 | |||
| CMPK1 | c.172-4418G>A | intron | N/A | NP_001129612.1 | A0A494BXC7 |
Ensembl Transcripts
| Sel. | Gene | Transcript | Tags | HGVSc | HGVSp | Effect | Exon Rank | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|---|
| CMPK1 | TSL:1 MANE Select | c.240G>A | p.Gln80Gln | synonymous | Exon 2 of 6 | ENSP00000360939.5 | P30085-3 | ||
| CMPK1 | c.240G>A | p.Gln80Gln | synonymous | Exon 2 of 6 | ENSP00000624841.1 | ||||
| CMPK1 | c.240G>A | p.Gln80Gln | synonymous | Exon 2 of 6 | ENSP00000624840.1 |
Frequencies
GnomAD3 genomes Cov.: 33
GnomAD4 exome Cov.: 30
GnomAD4 genome Cov.: 33
ClinVar
Not reported inComputational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at
MaxEntScan Visualizer can be used to analyze the impact of this mutation on the neighboring sequence.